Unbiased Selection of Peptide鈥揚eptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells
详细信息 查看全文
- 作者：Jaya M. Matharage ; John D. Minna ; Rolf A. Brekken ; D. Gomika Udugamasooriya
- 刊名：ACS Chemical Biology
- 出版年：2015
- 出版时间：December 18, 2015
- 年：2015
- 卷：10
- 期：12
- 页码：2891-2899
- 全文大小：519K
- ISSN：1554-8937
文摘
To develop widely applicable diagnostic and potentially therapeutic approaches overcoming protein heterogeneity in human cancer, we have developed a technology to unbiasedly select high specificity compound(s) that bind any biomolecule (e.g., proteins, lipids, carbohydrates) presented on the cancer cell surface but not on normal cells. We utilized a peptidomimetic based on-bead two-color (OBTC) combinatorial cell screen that can detect differences between two cell surfaces at high accuracy by looking for beads (where each bead in the library had one peptide鈥損eptoid hybrid on the surface) that only bound cancer but not normal cells. We screened a library of 393鈥?16 compounds targeting HCC4017 lung adenocarcinoma cells (labeled in red) in the presence of HBEC30KT normal bronchial epithelial cells (labeled in green) derived from the same tissue of the same patient. This screen identified a peptide鈥損eptoid hybrid called PPS1 which displayed high specific binding for HCC4017 cancer cells over HBEC30KT cells. Specificity was validated through on-bead, ELISA-like and magnetic bead pulldown studies, while a scrambled version of PPS1 did not show any binding. Of interest, the simple dimeric version (PPS1D1) displayed cytotoxic activity on HCC4017 cells, but not on normal HBEC30KT cells. PPS1D1 also strongly accumulated in HCC4017 lung cancer xenografts in mice over control constructs. We conclude that such combinatorial screens using tumor and normal cells from the same patient have significant potential to develop new reagents for cancer biology, diagnosis, and potentially therapy.